Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation
Status:
Recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
This study is an open, prospective, single arm, multi center exploratory basket clinical
study. 20 refractory solid tumors patients with rescuable p53 mutation will be enrolled, and
the efficacy and safety of arsenic trioxide in those patients will be evaluated.